Condition Lookup
Category:
Red Blood Cells and Disorders
Number of Conditions: 22
Anemia
Specialty: Hematology
Category: Red Blood Cells and Disorders
Symptoms:
fatigue; pale or yellowish skin; shortness of breath; dizziness; cold hands and feet; irregular heartbeat; chest pain
Root Cause:
A decrease in the number of red blood cells or hemoglobin, leading to reduced oxygen delivery to tissues. Causes include iron deficiency, vitamin deficiencies (B12 or folate), chronic diseases, and blood loss.
How it's Diagnosed: videos
Blood tests, including a complete blood count (CBC) to measure hemoglobin, hematocrit, and red blood cell indices. Additional tests may include ferritin, vitamin B12, folate levels, and reticulocyte count.
Treatment:
Treatment depends on the underlying cause. Common treatments include dietary supplements (iron, B12, folate), blood transfusions, and treating underlying chronic diseases or conditions.
Medications:
Iron supplements (e.g., ferrous sulfate, ferrous gluconate), vitamin B12 injections or oral supplements, folic acid supplements, erythropoiesis-stimulating agents (e.g., epoetin alfa or darbepoetin alfa) for anemia related to chronic disease or kidney failure.
Prevalence:
How common the health condition is within a specific population.
Affects approximately 1.62 billion people globally, with higher prevalence in women, children, and individuals in developing countries.
Risk Factors:
Factors or behaviors that increase the likelihood of developing the condition.
Poor diet, chronic illnesses (e.g., kidney disease, inflammatory conditions), heavy menstrual bleeding, pregnancy, gastrointestinal bleeding, and genetic conditions (e.g., sickle cell anemia).
Prognosis:
The expected outcome or course of the condition over time.
Good prognosis with appropriate treatment; prognosis depends on underlying cause. Untreated, it can lead to significant complications.
Complications:
Additional problems or conditions that may arise as a result of the original condition.
Heart problems (e.g., left ventricular hypertrophy, heart failure), delayed growth in children, and reduced ability to perform physical activities.
Anemia in Elderly Persons
Specialty: Hematology
Category: Red Blood Cells and Disorders
Symptoms:
weakness; fatigue; diminished physical performance; shortness of breath; increased susceptibility to falls; cognitive decline
Root Cause:
Often related to nutritional deficiencies, chronic inflammation, or age-related decline in erythropoiesis.
How it's Diagnosed: videos
Complete blood count (CBC), ferritin levels, serum iron, total iron-binding capacity (TIBC), and tests for vitamin B12 and folate levels. Additional testing may investigate chronic diseases.
Treatment:
Address underlying causes, including dietary deficiencies or chronic diseases. Erythropoiesis-stimulating agents may be used in some cases.
Medications:
Oral or intravenous iron, vitamin B12 injections, folic acid, and erythropoietin-stimulating agents such as epoetin alfa.
Prevalence:
How common the health condition is within a specific population.
Common in elderly populations, affecting approximately 10% of people over 65 years.
Risk Factors:
Factors or behaviors that increase the likelihood of developing the condition.
Advanced age, chronic diseases (e.g., kidney disease, inflammatory disorders), malnutrition, and medications interfering with absorption of nutrients.
Prognosis:
The expected outcome or course of the condition over time.
Dependent on identifying and managing the cause. Nutritional deficiencies often respond well to treatment, while chronic disease-associated anemia may require long-term management.
Complications:
Additional problems or conditions that may arise as a result of the original condition.
Increased mortality, cardiovascular events, frailty, and reduced quality of life.
Anemia of Chronic Disease and Kidney Failure
Specialty: Hematology
Category: Red Blood Cells and Disorders
Symptoms:
fatigue; weakness; shortness of breath; pale skin; reduced exercise tolerance; dizziness; cold hands and feet
Root Cause:
Decreased red blood cell production due to chronic inflammation or reduced erythropoietin production by the kidneys. Additional factors include iron-restricted erythropoiesis and shortened red blood cell lifespan.
How it's Diagnosed: videos
Complete blood count (CBC) showing low hemoglobin and hematocrit, serum iron and ferritin levels, transferrin saturation, erythropoietin levels, and evaluation of kidney function through creatinine and glomerular filtration rate (GFR).
Treatment:
Management of the underlying chronic condition (e.g., controlling inflammation or treating kidney disease) and replenishment of iron stores and erythropoiesis support.
Medications:
Iron supplementation (oral or intravenous), erythropoiesis-stimulating agents (e.g., epoetin alfa, darbepoetin alfa), and vitamin B12 or folate if deficiencies exist.
Prevalence:
How common the health condition is within a specific population.
Anemia of chronic disease is the second most common type of anemia worldwide. It is highly prevalent in patients with chronic kidney disease (CKD), affecting up to 90% of individuals with end-stage kidney disease.
Risk Factors:
Factors or behaviors that increase the likelihood of developing the condition.
Chronic illnesses (e.g., kidney disease, autoimmune diseases, cancer), inflammation, diabetes, hypertension, and older age.
Prognosis:
The expected outcome or course of the condition over time.
The prognosis depends on the severity of the underlying condition and the response to treatment. With appropriate management, anemia can be controlled, improving quality of life and reducing complications.
Complications:
Additional problems or conditions that may arise as a result of the original condition.
Left ventricular hypertrophy, heart failure, reduced quality of life, increased hospitalization rates, and higher mortality in severe cases of untreated anemia.
Aplastic Anemia
Specialty: Hematology
Category: Red Blood Cells and Disorders
Symptoms:
fatigue; shortness of breath; frequent infections; unexplained or easy bruising; prolonged bleeding from cuts; pale skin; dizziness; headache; rapid or irregular heartbeat
Root Cause:
A rare condition in which the bone marrow fails to produce sufficient red blood cells, white blood cells, and platelets. Causes include autoimmune damage, exposure to toxic chemicals, certain medications, radiation, viral infections, or inherited conditions.
How it's Diagnosed: videos
Blood tests showing pancytopenia (low levels of all blood cells) and reticulocytopenia (low reticulocyte count). Bone marrow biopsy confirms hypocellular (empty) or fatty bone marrow.
Treatment:
Treatment depends on severity. Mild cases may involve supportive care, while severe cases often require immunosuppressive therapy, hematopoietic stem cell transplantation (bone marrow transplant), or blood transfusions.
Medications:
Immunosuppressants (e.g., antithymocyte globulin [ATG], cyclosporine , corticosteroids), hematopoietic growth factors (e.g., filgrastim or sargramostim ), androgens (e.g., danazol ) in certain cases, and antibiotics or antifungals to prevent or treat infections.
Prevalence:
How common the health condition is within a specific population.
Rare, affecting approximately 1-2 individuals per million people annually worldwide, with higher incidence in Asia.
Risk Factors:
Factors or behaviors that increase the likelihood of developing the condition.
Exposure to toxic chemicals (e.g., benzene), radiation or chemotherapy, certain medications (e.g., chloramphenicol), viral infections (e.g., hepatitis, Epstein-Barr virus), autoimmune diseases, and genetic predisposition (e.g., Fanconi anemia).
Prognosis:
The expected outcome or course of the condition over time.
With treatment, prognosis varies. Bone marrow transplantation offers a potential cure for eligible patients. Immunosuppressive therapy is effective for many, though relapses can occur. Without treatment, severe aplastic anemia is often fatal.
Complications:
Additional problems or conditions that may arise as a result of the original condition.
Life-threatening infections, severe bleeding, iron overload from repeated transfusions, progression to myelodysplastic syndrome or leukemia, and organ damage from iron overload.
Argyria
Specialty: Hematology
Category: Red Blood Cells and Disorders
Symptoms:
permanent bluish-gray discoloration of the skin and mucous membranes; discoloration more prominent in areas exposed to sunlight; nail discoloration; eye sclera discoloration
Root Cause:
Deposition of silver particles in the skin and other tissues due to chronic exposure or excessive intake of silver compounds. Silver reacts with light, causing a photochemical reaction that leads to the characteristic discoloration.
How it's Diagnosed: videos
Diagnosis is based on clinical appearance (bluish-gray discoloration), history of silver exposure or ingestion, and biopsy of affected tissue showing silver deposition.
Treatment:
There is no effective treatment to reverse the discoloration. Preventative measures include avoiding excessive exposure to silver-containing substances. Cosmetic treatments, such as laser therapy, may reduce discoloration in some cases.
Medications:
There are no specific medications to treat argyria. Management focuses on preventing further exposure to silver and addressing any secondary issues.
Prevalence:
How common the health condition is within a specific population.
Extremely rare; occurs in individuals with prolonged or excessive exposure to silver-containing products (e.g., industrial exposure, alternative medicine use).
Risk Factors:
Factors or behaviors that increase the likelihood of developing the condition.
Chronic use of colloidal silver products, occupational exposure to silver compounds, and ingestion of silver salts.
Prognosis:
The expected outcome or course of the condition over time.
While the condition is not life-threatening, the discoloration is permanent and can lead to psychological distress or social stigma. Prognosis improves with prevention of further silver exposure.
Complications:
Additional problems or conditions that may arise as a result of the original condition.
Psychological impact due to cosmetic appearance, social isolation, and rarely, deposition of silver in internal organs, leading to organ dysfunction in extreme cases.
Beta Thalassemia
Specialty: Hematology
Category: Red Blood Cells and Disorders
Symptoms:
fatigue; weakness; pale or yellowish skin; dark urine; slow growth; bone deformities; enlarged spleen
Root Cause:
A genetic mutation reduces the production of beta-globin chains in hemoglobin, leading to ineffective red blood cell production and anemia.
How it's Diagnosed: videos
Complete blood count (CBC), hemoglobin electrophoresis, genetic testing, and peripheral blood smear.
Treatment:
Regular blood transfusions, iron chelation therapy, bone marrow or stem cell transplant, and supportive care.
Medications:
Iron chelators like deferasirox or deferoxamine to manage iron overload from transfusions. Folic acid supplements may also be prescribed.
Prevalence:
How common the health condition is within a specific population.
More common in Mediterranean, Middle Eastern, and Southeast Asian populations; worldwide incidence is around 1 in 100,000.
Risk Factors:
Factors or behaviors that increase the likelihood of developing the condition.
Family history of thalassemia, carrier status for beta-thalassemia mutations, consanguineous marriage.
Prognosis:
The expected outcome or course of the condition over time.
Life expectancy depends on severity; regular treatment improves quality of life but severe cases require lifelong care.
Complications:
Additional problems or conditions that may arise as a result of the original condition.
Iron overload, heart disease, liver damage, endocrine dysfunction, and bone abnormalities.
Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency
Specialty: Hematology
Category: Red Blood Cells and Disorders
Sub-category: Hemolytic Anemia
Symptoms:
fatigue; dark urine; jaundice; pallor; shortness of breath; rapid heart rate
Root Cause:
Deficiency in the G6PD enzyme makes red blood cells vulnerable to oxidative stress, leading to hemolysis.
How it's Diagnosed: videos
G6PD enzyme activity assay, CBC, and peripheral blood smear.
Treatment:
Avoidance of triggers (e.g., certain drugs, fava beans, infections), supportive care during hemolytic episodes, and blood transfusions if severe.
Medications:
No specific medications; management focuses on avoiding oxidative stress.
Prevalence:
How common the health condition is within a specific population.
Common in malaria-endemic regions, affecting approximately 400 million people globally.
Risk Factors:
Factors or behaviors that increase the likelihood of developing the condition.
Male sex (X-linked condition), African, Mediterranean, or Asian ancestry.
Prognosis:
The expected outcome or course of the condition over time.
Generally good with trigger avoidance; hemolytic episodes are self-limiting.
Complications:
Additional problems or conditions that may arise as a result of the original condition.
Acute hemolysis, neonatal jaundice, and potential kidney damage during severe episodes.
Hemoglobin C Disease
Specialty: Hematology
Category: Red Blood Cells and Disorders
Symptoms:
fatigue; mild anemia; jaundice; splenomegaly; episodic pain crises in severe cases
Root Cause:
A genetic mutation in the HBB gene leads to the production of hemoglobin C, which causes red blood cells to become more rigid and prone to destruction.
How it's Diagnosed: videos
Hemoglobin electrophoresis, complete blood count (CBC), peripheral blood smear, and genetic testing for the HBB gene mutation.
Treatment:
Treatment is often supportive, focusing on managing anemia and preventing complications. Severe cases may require splenectomy or blood transfusions during crises.
Medications:
Folic acid supplements to support red blood cell production; no specific pharmacological treatment for the condition itself. Pain management medications may be prescribed for crises.
Prevalence:
How common the health condition is within a specific population.
Predominantly affects individuals of African or Mediterranean descent, with a carrier rate of approximately 2-3% in African populations.
Risk Factors:
Factors or behaviors that increase the likelihood of developing the condition.
Having parents who are carriers of the hemoglobin C trait.
Prognosis:
The expected outcome or course of the condition over time.
Generally good; most individuals have mild symptoms and live normal lifespans, but severe cases may experience more complications.
Complications:
Additional problems or conditions that may arise as a result of the original condition.
Splenomegaly, gallstones, increased risk of infections post-splenectomy, and rare severe hemolytic anemia crises.
Hemoglobinopathy Retinopathy
Specialty: Hematology
Category: Red Blood Cells and Disorders
Symptoms:
visual disturbances; blurry vision; floaters; peripheral vision loss
Root Cause:
Abnormal hemoglobin leads to occlusion of retinal blood vessels, ischemia, and subsequent retinal damage.
How it's Diagnosed: videos
Fundoscopic examination, fluorescein angiography, optical coherence tomography (OCT), and hemoglobin electrophoresis to identify the underlying hemoglobinopathy.
Treatment:
Treatment involves managing the underlying hemoglobinopathy, laser photocoagulation for neovascularization, and anti-VEGF injections for retinal edema.
Medications:
Anti-VEGF agents (e.g., ranibizumab , aflibercept ) to reduce retinal edema; folic acid and hydroxyurea for underlying hemoglobinopathy management.
Prevalence:
How common the health condition is within a specific population.
Associated with hemoglobinopathies like sickle cell disease; prevalence varies based on hemoglobinopathy distribution.
Risk Factors:
Factors or behaviors that increase the likelihood of developing the condition.
Underlying hemoglobinopathies (e.g., sickle cell disease, hemoglobin SC disease), poorly managed systemic symptoms.
Prognosis:
The expected outcome or course of the condition over time.
Variable; early diagnosis and treatment improve outcomes, but untreated retinopathy can lead to significant vision loss.
Complications:
Additional problems or conditions that may arise as a result of the original condition.
Retinal detachment, vitreous hemorrhage, permanent vision loss.
Hemolytic Anemia
Specialty: Hematology
Category: Red Blood Cells and Disorders
Symptoms:
fatigue; jaundice; pallor; dark urine; splenomegaly; shortness of breath
Root Cause:
Premature destruction of red blood cells leads to anemia and increased production of bilirubin. Causes include autoimmune reactions, genetic disorders, infections, and medications.
How it's Diagnosed: videos
Complete blood count (CBC), reticulocyte count, bilirubin levels, Coombs test, and peripheral blood smear.
Treatment:
Treatment depends on the cause and may include corticosteroids for autoimmune causes, plasmapheresis, or blood transfusions. Splenectomy may be necessary in chronic cases.
Medications:
Corticosteroids (e.g., prednisone ) for autoimmune hemolytic anemia; rituximab for refractory cases; folic acid to support red blood cell production.
Prevalence:
How common the health condition is within a specific population.
Varies widely depending on the cause; autoimmune hemolytic anemia affects 1-3 per 100,000 annually.
Risk Factors:
Factors or behaviors that increase the likelihood of developing the condition.
Autoimmune disorders, infections, hereditary conditions (e.g., G6PD deficiency, sickle cell disease), and certain medications.
Prognosis:
The expected outcome or course of the condition over time.
Prognosis depends on the underlying cause; manageable with appropriate treatment in most cases.
Complications:
Additional problems or conditions that may arise as a result of the original condition.
Severe anemia, heart failure, gallstones, and increased susceptibility to infections.
Iron Deficiency Anemia
Specialty: Hematology
Category: Red Blood Cells and Disorders
Symptoms:
fatigue; weakness; pallor; shortness of breath; brittle nails; pica; cold intolerance
Root Cause:
Insufficient iron levels lead to reduced hemoglobin production, impairing oxygen delivery to tissues.
How it's Diagnosed: videos
Complete blood count (CBC), serum ferritin, serum iron, total iron-binding capacity (TIBC), and transferrin saturation.
Treatment:
Iron supplementation (oral or intravenous), dietary modifications, and addressing the underlying cause of iron loss.
Medications:
Ferrous sulfate (oral iron supplement), ferric carboxymaltose (IV iron for severe cases), erythropoiesis-stimulating agents in chronic diseases.
Prevalence:
How common the health condition is within a specific population.
The most common nutritional deficiency worldwide, affecting up to 25% of the global population.
Risk Factors:
Factors or behaviors that increase the likelihood of developing the condition.
Poor dietary intake, chronic blood loss (e.g., heavy menstruation, gastrointestinal bleeding), pregnancy, and malabsorption disorders.
Prognosis:
The expected outcome or course of the condition over time.
Excellent with appropriate treatment; symptoms resolve as iron levels normalize.
Complications:
Additional problems or conditions that may arise as a result of the original condition.
Severe anemia, delayed growth in children, heart failure, and increased susceptibility to infections.
Macrocytosis
Specialty: Hematology
Category: Red Blood Cells and Disorders
Symptoms:
fatigue; weakness; shortness of breath; pallor; neurological symptoms in cases of vitamin b12 deficiency
Root Cause:
Enlargement of red blood cells due to vitamin B12 or folate deficiency, liver disease, or bone marrow disorders.
How it's Diagnosed: videos
Complete blood count (CBC), peripheral blood smear, vitamin B12 and folate levels, liver function tests, and bone marrow biopsy if needed.
Treatment:
Addressing the underlying cause, such as supplementation for vitamin B12 or folate deficiency or treatment of liver disease.
Medications:
Vitamin B12 injections or oral supplementation; folic acid supplements; hydroxyurea in certain bone marrow disorders.
Prevalence:
How common the health condition is within a specific population.
Common, particularly in older adults or individuals with dietary deficiencies or chronic illnesses.
Risk Factors:
Factors or behaviors that increase the likelihood of developing the condition.
Vitamin B12 or folate deficiency, alcohol use, liver disease, hypothyroidism, and bone marrow disorders.
Prognosis:
The expected outcome or course of the condition over time.
Good with appropriate treatment; reversible in most cases.
Complications:
Additional problems or conditions that may arise as a result of the original condition.
Severe anemia, neurological deficits in vitamin B12 deficiency, and progression to bone marrow disorders.
Megaloblastic Anemia
Specialty: Hematology
Category: Red Blood Cells and Disorders
Symptoms:
fatigue; pale or yellowish skin; shortness of breath; weakness; irritability; numbness or tingling in hands and feet; difficulty concentrating; glossitis (swollen, red tongue); loss of appetite
Root Cause:
A defect in DNA synthesis caused by deficiencies in vitamin B12 or folate, leading to the production of abnormally large and immature red blood cells (megaloblasts) in the bone marrow.
How it's Diagnosed: videos
Blood tests showing macrocytosis (large red blood cells), hypersegmented neutrophils, low vitamin B12 or folate levels, elevated homocysteine, and possibly elevated methylmalonic acid (specific for B12 deficiency). A bone marrow biopsy may confirm megaloblastic changes.
Treatment:
Treatment depends on the underlying deficiency. Supplementation of vitamin B12 (oral or intramuscular injections) or folate, along with dietary modifications to include foods rich in these nutrients.
Medications:
Vitamin B12 supplements (cyanocobalamin or hydroxocobalamin ) — classified as vitamin therapy. Folic acid supplements — also classified as vitamin therapy. Combination therapy with both vitamin B12 and folic acid if the deficiency is unclear.
Prevalence:
How common the health condition is within a specific population.
Varies by region; more common in areas with dietary deficiencies or high rates of malabsorption disorders (e.g., pernicious anemia). Common among older adults and populations with limited access to fortified foods.
Risk Factors:
Factors or behaviors that increase the likelihood of developing the condition.
dietary deficiency of vitamin B12 or folate; alcoholism; pregnancy; pernicious anemia; gastrointestinal surgeries (e.g., gastrectomy); malabsorption conditions (e.g., celiac disease, Crohn's disease); medications interfering with vitamin absorption (e.g., methotrexate, metformin, proton pump inhibitors)
Prognosis:
The expected outcome or course of the condition over time.
With appropriate supplementation and treatment of the underlying cause, symptoms typically resolve, and prognosis is excellent. Untreated cases can lead to irreversible neurological damage in vitamin B12 deficiency.
Complications:
Additional problems or conditions that may arise as a result of the original condition.
irreversible neurological damage; infertility; cardiovascular risks due to elevated homocysteine levels; increased susceptibility to infections; peripheral neuropathy; cognitive decline or memory issues
Methemoglobinemia
Specialty: Hematology
Category: Red Blood Cells and Disorders
Symptoms:
cyanosis (bluish skin, especially lips and fingers); shortness of breath; fatigue; confusion; headache; dizziness; tachycardia; loss of consciousness in severe cases
Root Cause:
Elevated levels of methemoglobin (an oxidized form of hemoglobin that cannot bind oxygen effectively) in the blood, leading to reduced oxygen delivery to tissues.
How it's Diagnosed: videos
Arterial blood gas analysis showing low oxygen saturation despite normal oxygen levels, co-oximetry detecting elevated methemoglobin levels, and a chocolate-brown appearance of arterial blood.
Treatment:
Treatment depends on severity. Methylene blue (an antidote) is administered intravenously in severe cases. Ascorbic acid may also help in mild cases. Removal of the causative agent (e.g., drugs or toxins) is crucial.
Medications:
Methylene blue — a reducing agent to convert methemoglobin back to functional hemoglobin. Ascorbic acid (Vitamin C) — classified as an antioxidant, used in mild chronic cases.
Prevalence:
How common the health condition is within a specific population.
Rare; often seen in people exposed to oxidizing agents (e.g., nitrates, dapsone, or benzocaine). Can also be congenital due to genetic mutations.
Risk Factors:
Factors or behaviors that increase the likelihood of developing the condition.
exposure to oxidizing drugs or chemicals; genetic predisposition (e.g., cytochrome b5 reductase deficiency); infants under 6 months (due to immature enzyme systems); industrial exposure to nitrates
Prognosis:
The expected outcome or course of the condition over time.
Prognosis is excellent with prompt treatment. Chronic or untreated cases may result in tissue hypoxia and severe complications.
Complications:
Additional problems or conditions that may arise as a result of the original condition.
hypoxia; seizures; cardiovascular collapse; death in severe untreated cases
Myelophthisic Anemia
Specialty: Hematology
Category: Red Blood Cells and Disorders
Symptoms:
fatigue; pallor; weakness; shortness of breath; easy bruising; frequent infections; bone pain in some cases
Root Cause:
Bone marrow failure caused by infiltration of abnormal cells or substances (e.g., cancer cells, fibrosis, granulomas), displacing normal hematopoietic tissue.
How it's Diagnosed: videos
Blood smear showing immature blood cells (leukoerythroblastosis), anemia, and abnormal red cell shapes. Bone marrow biopsy confirms marrow infiltration.
Treatment:
Treatment depends on the underlying cause (e.g., chemotherapy for cancer, corticosteroids for fibrosis, or infection management). Supportive measures include transfusions.
Medications:
Specific to the underlying cause (e.g., chemotherapy for malignancies, corticosteroids for granulomatous diseases). Erythropoietin-stimulating agents to support red blood cell production in some cases.
Prevalence:
How common the health condition is within a specific population.
Rare, primarily associated with malignancies (e.g., metastatic cancer, leukemia, lymphoma) or chronic infections (e.g., tuberculosis).
Risk Factors:
Factors or behaviors that increase the likelihood of developing the condition.
malignancies; chronic granulomatous infections; fibrotic disorders; radiation exposure; certain genetic predispositions
Prognosis:
The expected outcome or course of the condition over time.
Prognosis depends on the underlying condition. Early diagnosis and treatment of the causative factor can improve outcomes.
Complications:
Additional problems or conditions that may arise as a result of the original condition.
severe anemia; organ failure due to infiltration; increased susceptibility to infections; bleeding disorders
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Specialty: Hematology
Category: Red Blood Cells and Disorders
Symptoms:
dark-colored urine (often in the morning); fatigue; weakness; shortness of breath; abdominal pain; difficulty swallowing; blood clots; jaundice
Root Cause:
A rare acquired mutation in the PIGA gene, leading to defective complement regulation on red blood cells and resulting in hemolysis (destruction of red blood cells).
How it's Diagnosed: videos
Flow cytometry detecting absent GPI-anchored proteins (e.g., CD55, CD59) on blood cells, lactate dehydrogenase (LDH) elevation, and hemoglobinuria.
Treatment:
Eculizumab (a complement inhibitor) is the main treatment. Supportive therapies include blood transfusions, iron supplementation, and anticoagulation for thrombosis.
Medications:
Eculizumab (Soliris ) — classified as a complement inhibitor, reduces hemolysis and thrombosis risk. Ravulizumab — a longer-acting complement inhibitor. Anticoagulants — used to prevent or treat thrombosis.
Prevalence:
How common the health condition is within a specific population.
Rare; affects 1-2 per million people annually. More common in young adults and associated with aplastic anemia or bone marrow failure syndromes.
Risk Factors:
Factors or behaviors that increase the likelihood of developing the condition.
genetic predisposition; association with aplastic anemia; exposure to certain toxins; immune dysregulation
Prognosis:
The expected outcome or course of the condition over time.
Improved significantly with complement inhibitors; however, untreated cases have a high risk of thrombosis and early mortality.
Complications:
Additional problems or conditions that may arise as a result of the original condition.
thrombosis; kidney failure; chronic hemolysis; iron overload from transfusions; pulmonary hypertension
Pernicious Anemia
Specialty: Hematology
Category: Red Blood Cells and Disorders
Symptoms:
fatigue; weakness; pale or jaundiced skin; shortness of breath; numbness or tingling in the hands and feet; difficulty walking; memory problems; mood changes; glossitis (sore, red tongue); loss of appetite
Root Cause:
Autoimmune destruction of gastric parietal cells leads to a lack of intrinsic factor, which is necessary for vitamin B12 absorption, resulting in impaired red blood cell production.
How it's Diagnosed: videos
Complete blood count (CBC), vitamin B12 levels, methylmalonic acid (MMA) levels, intrinsic factor antibody test, and bone marrow biopsy (if needed).
Treatment:
Vitamin B12 supplementation through injections or high-dose oral supplements, along with management of any neurological symptoms or complications.
Medications:
Vitamin B12 (cyanocobalamin or hydroxocobalamin ), typically administered intramuscularly or subcutaneously. These medications are classified as vitamins and nutritional supplements.
Prevalence:
How common the health condition is within a specific population.
Common in individuals over 60 years old; higher prevalence in people of Northern European descent and those with autoimmune conditions.
Risk Factors:
Factors or behaviors that increase the likelihood of developing the condition.
Autoimmune conditions (e.g., Hashimoto's thyroiditis, type 1 diabetes), family history, vegetarian or vegan diets (due to low dietary B12), and gastrointestinal surgeries or disorders (e.g., gastric bypass, chronic gastritis).
Prognosis:
The expected outcome or course of the condition over time.
Excellent with timely treatment; symptoms and hematologic abnormalities often resolve with B12 replacement therapy. Delayed treatment may lead to irreversible neurological damage.
Complications:
Additional problems or conditions that may arise as a result of the original condition.
Neurological symptoms (e.g., peripheral neuropathy, cognitive impairment), increased risk of gastric cancer, and severe anemia.
Pure Red Cell Aplasia (PRCA)
Specialty: Hematology
Category: Red Blood Cells and Disorders
Symptoms:
severe fatigue; pallor; shortness of breath; dizziness; tachycardia (rapid heartbeat); headaches
Root Cause:
Selective suppression or destruction of red blood cell precursors in the bone marrow, often due to autoimmune mechanisms, viral infections (e.g., parvovirus B19), or medications.
How it's Diagnosed: videos
Complete blood count (CBC) showing severe anemia with low reticulocyte count, bone marrow biopsy revealing absence or reduction of red blood cell precursors, and testing for associated infections or autoimmune markers.
Treatment:
Treated based on the underlying cause and includes immunosuppressive therapy (e.g., corticosteroids, cyclosporine, or rituximab), antiviral medications for parvovirus B19 infection, and in some cases, plasmapheresis or supportive care with red blood cell transfusions.
Medications:
Corticosteroids (e.g., prednisone , dexamethasone ), immunosuppressants (e.g., cyclosporine , tacrolimus ), and intravenous immunoglobulin (IVIG) for autoimmune causes. These medications are classified as immunosuppressants or anti-inflammatory agents.
Prevalence:
How common the health condition is within a specific population.
Rare, with an incidence of 1–5 cases per million people annually; can occur in any age group.
Risk Factors:
Factors or behaviors that increase the likelihood of developing the condition.
Autoimmune diseases (e.g., rheumatoid arthritis), exposure to certain medications (e.g., isoniazid, phenytoin), infections (e.g., parvovirus B19, Epstein-Barr virus), and hematologic malignancies (e.g., leukemia).
Prognosis:
The expected outcome or course of the condition over time.
Variable; may resolve spontaneously if caused by infection or medication. Chronic or idiopathic cases may require long-term immunosuppressive therapy.
Complications:
Additional problems or conditions that may arise as a result of the original condition.
Severe anemia requiring transfusions, iron overload from chronic transfusions, and progression to aplastic anemia or other bone marrow disorders.
Sickle Cell Disease (SCD)
Specialty: Hematology
Category: Red Blood Cells and Disorders
Symptoms:
chronic anemia; pain crises; fatigue; swelling in hands and feet; delayed growth; frequent infections; jaundice; vision problems
Root Cause:
Genetic mutation in the HBB gene causes production of abnormal hemoglobin (HbS), leading to red blood cells that sickle under low oxygen conditions, resulting in hemolysis and vascular occlusion.
How it's Diagnosed: videos
Hemoglobin electrophoresis, genetic testing, blood smear showing sickled cells, and complete blood count (CBC).
Treatment:
Hydroxyurea to reduce pain crises and transfusion frequency, blood transfusions, stem cell transplant (potential cure in select cases), and supportive care.
Medications:
Hydroxyurea (increases fetal hemoglobin production), L-glutamine (reduces oxidative stress), voxelotor (inhibits HbS polymerization), and crizanlizumab (reduces vaso-occlusive crises).
Prevalence:
How common the health condition is within a specific population.
Affects millions globally, particularly individuals of African, Mediterranean, Middle Eastern, and Indian descent. In the U.S., it affects approximately 1 in 365 African-American births.
Risk Factors:
Factors or behaviors that increase the likelihood of developing the condition.
Family history of SCD, being a carrier (sickle cell trait) with a partner who is also a carrier.
Prognosis:
The expected outcome or course of the condition over time.
With modern treatments, life expectancy has improved, but complications may limit quality of life. Stem cell transplant offers a potential cure in select cases.
Complications:
Additional problems or conditions that may arise as a result of the original condition.
Stroke, acute chest syndrome, organ damage (kidney, liver, spleen), chronic pain, and increased risk of infections.
Sideroblastic Anemias
Specialty: Hematology
Category: Red Blood Cells and Disorders
Symptoms:
fatigue; weakness; pallor; shortness of breath; dizziness; irritability; enlarged spleen or liver
Root Cause:
Defective hemoglobin synthesis due to impaired incorporation of iron into heme, resulting in iron buildup in mitochondria of erythroblasts (ringed sideroblasts in the bone marrow).
How it's Diagnosed: videos
Bone marrow biopsy showing ringed sideroblasts, complete blood count (CBC) with anemia, peripheral blood smear, and iron studies (elevated serum iron and ferritin). Genetic testing for hereditary causes.
Treatment:
reated by addressing the underlying cause, with options including pyridoxine (vitamin B6) supplementation for hereditary forms, management of contributing factors like alcohol or toxins, iron chelation therapy for iron overload, and transfusions for severe anemia.
Medications:
Pyridoxine (vitamin B6) for hereditary forms, iron chelators such as deferoxamine , deferiprone , or deferasirox to manage iron overload.
Prevalence:
How common the health condition is within a specific population.
Rare; hereditary forms are often seen in childhood, while acquired forms are more common in adults, especially in myelodysplastic syndromes.
Risk Factors:
Factors or behaviors that increase the likelihood of developing the condition.
Genetic mutations (e.g., ALAS2 gene), alcohol use, lead poisoning, certain medications (e.g., isoniazid, chloramphenicol), and myelodysplastic syndromes.
Prognosis:
The expected outcome or course of the condition over time.
Variable; hereditary forms respond well to pyridoxine, while acquired forms depend on the underlying cause. Iron overload can lead to complications without proper management.
Complications:
Additional problems or conditions that may arise as a result of the original condition.
Severe anemia, organ damage from iron overload (e.g., heart, liver, endocrine glands), and progression to myelodysplastic syndrome or acute myeloid leukemia in some cases.
Thalassemia Intermedia
Specialty: Hematology
Category: Red Blood Cells and Disorders
Symptoms:
mild to moderate anemia; fatigue; weakness; delayed growth; bone deformities; jaundice; enlarged spleen
Root Cause:
Reduced production of either alpha or beta globin chains in hemoglobin, leading to ineffective erythropoiesis and hemolysis.
How it's Diagnosed: videos
Hemoglobin electrophoresis, genetic testing, complete blood count (CBC) showing microcytic hypochromic anemia, and blood smear.
Treatment:
Blood transfusions during stress or pregnancy, folic acid supplementation, management of iron overload with chelation therapy, and splenectomy in severe cases.
Medications:
Folic acid supplements, iron chelators (e.g., deferoxamine , deferiprone , deferasirox ). Hydroxyurea may be used in select cases to increase fetal hemoglobin.
Prevalence:
How common the health condition is within a specific population.
Varies by region; more common in Mediterranean, Middle Eastern, Southeast Asian, and African populations.
Risk Factors:
Factors or behaviors that increase the likelihood of developing the condition.
Family history of thalassemia, being a carrier of the beta or alpha thalassemia trait.
Prognosis:
The expected outcome or course of the condition over time.
Better than thalassemia major but may require lifelong management. Risk of complications increases without proper treatment.
Complications:
Additional problems or conditions that may arise as a result of the original condition.
Iron overload from transfusions, bone deformities, growth delays, and increased risk of thrombosis.
Transfusion-Induced Iron Overload
Specialty: Hematology
Category: Red Blood Cells and Disorders
Symptoms:
fatigue; joint pain; darkened skin; abdominal pain; heart palpitations; shortness of breath
Root Cause:
Repeated blood transfusions lead to excessive iron accumulation in tissues, as the body cannot excrete the excess iron.
How it's Diagnosed: videos
Serum ferritin levels, transferrin saturation, liver MRI to assess iron deposition, and liver biopsy in certain cases.
Treatment:
Iron chelation therapy to remove excess iron and minimize organ damage. Lifestyle modifications, such as reducing dietary iron intake.
Medications:
Deferoxamine (parenteral), deferasirox (oral), and deferiprone (oral). These are classified as iron chelators.
Prevalence:
How common the health condition is within a specific population.
Common in patients receiving chronic transfusions for conditions such as thalassemia, sickle cell disease, and myelodysplastic syndromes.
Risk Factors:
Factors or behaviors that increase the likelihood of developing the condition.
Frequent blood transfusions, hereditary hemochromatosis, ineffective erythropoiesis.
Prognosis:
The expected outcome or course of the condition over time.
Good with early detection and treatment, but untreated cases can lead to significant organ damage.
Complications:
Additional problems or conditions that may arise as a result of the original condition.
Organ damage (heart, liver, pancreas), diabetes, cirrhosis, and heart failure.